Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes

Douglas S. Taylor, Yisheng Lee, Colin A. Sieff, Alan Homans, Leslie Garrison, Eva C. Guinan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Fourteen paediatric patients with advanced amegakaryocytic thrombocytopenia (AMT) or other bone marrow (BM) failure syndromes were enrolled on one of two phase I/II dose escalation studies of PIXY321. PIXY321 was administered subcutaneously in doses ranging from 250 to 750mg/m2/d. No dose-limiting toxicity was observed. Peak absolute neutrophil count (ANC) was higher than baseline in all patients. Most transfusion-independent patients demonstrated elevation in haematocrit and/or platelet count. Trilineage haemopoietic responsiveness was evident in the three transfusion-independent patients. In these paediatric populations PIXY321 is well tolerated and merits consideration as a potential therapy.

Original languageEnglish (US)
Pages (from-to)304-307
Number of pages4
JournalBritish Journal of Haematology
Volume103
Issue number2
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Interleukin-3
Granulocyte-Macrophage Colony-Stimulating Factor
Bone Marrow
Proteins
Pediatrics
Therapeutics
Platelet Count
Hematocrit
Thrombocytopenia
Neutrophils
Population

Keywords

  • Bone marrow failure
  • Children
  • Growth factor
  • Lymphokine
  • PIXY321

ASJC Scopus subject areas

  • Hematology

Cite this

Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes. / Taylor, Douglas S.; Lee, Yisheng; Sieff, Colin A.; Homans, Alan; Garrison, Leslie; Guinan, Eva C.

In: British Journal of Haematology, Vol. 103, No. 2, 1998, p. 304-307.

Research output: Contribution to journalArticle

Taylor, Douglas S. ; Lee, Yisheng ; Sieff, Colin A. ; Homans, Alan ; Garrison, Leslie ; Guinan, Eva C. / Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes. In: British Journal of Haematology. 1998 ; Vol. 103, No. 2. pp. 304-307.
@article{280470bdf85947a480be9e0983f7a266,
title = "Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes",
abstract = "Fourteen paediatric patients with advanced amegakaryocytic thrombocytopenia (AMT) or other bone marrow (BM) failure syndromes were enrolled on one of two phase I/II dose escalation studies of PIXY321. PIXY321 was administered subcutaneously in doses ranging from 250 to 750mg/m2/d. No dose-limiting toxicity was observed. Peak absolute neutrophil count (ANC) was higher than baseline in all patients. Most transfusion-independent patients demonstrated elevation in haematocrit and/or platelet count. Trilineage haemopoietic responsiveness was evident in the three transfusion-independent patients. In these paediatric populations PIXY321 is well tolerated and merits consideration as a potential therapy.",
keywords = "Bone marrow failure, Children, Growth factor, Lymphokine, PIXY321",
author = "Taylor, {Douglas S.} and Yisheng Lee and Sieff, {Colin A.} and Alan Homans and Leslie Garrison and Guinan, {Eva C.}",
year = "1998",
doi = "10.1046/j.1365-2141.1998.01012.x",
language = "English (US)",
volume = "103",
pages = "304--307",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes

AU - Taylor, Douglas S.

AU - Lee, Yisheng

AU - Sieff, Colin A.

AU - Homans, Alan

AU - Garrison, Leslie

AU - Guinan, Eva C.

PY - 1998

Y1 - 1998

N2 - Fourteen paediatric patients with advanced amegakaryocytic thrombocytopenia (AMT) or other bone marrow (BM) failure syndromes were enrolled on one of two phase I/II dose escalation studies of PIXY321. PIXY321 was administered subcutaneously in doses ranging from 250 to 750mg/m2/d. No dose-limiting toxicity was observed. Peak absolute neutrophil count (ANC) was higher than baseline in all patients. Most transfusion-independent patients demonstrated elevation in haematocrit and/or platelet count. Trilineage haemopoietic responsiveness was evident in the three transfusion-independent patients. In these paediatric populations PIXY321 is well tolerated and merits consideration as a potential therapy.

AB - Fourteen paediatric patients with advanced amegakaryocytic thrombocytopenia (AMT) or other bone marrow (BM) failure syndromes were enrolled on one of two phase I/II dose escalation studies of PIXY321. PIXY321 was administered subcutaneously in doses ranging from 250 to 750mg/m2/d. No dose-limiting toxicity was observed. Peak absolute neutrophil count (ANC) was higher than baseline in all patients. Most transfusion-independent patients demonstrated elevation in haematocrit and/or platelet count. Trilineage haemopoietic responsiveness was evident in the three transfusion-independent patients. In these paediatric populations PIXY321 is well tolerated and merits consideration as a potential therapy.

KW - Bone marrow failure

KW - Children

KW - Growth factor

KW - Lymphokine

KW - PIXY321

UR - http://www.scopus.com/inward/record.url?scp=0031724209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031724209&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1998.01012.x

DO - 10.1046/j.1365-2141.1998.01012.x

M3 - Article

C2 - 9827896

AN - SCOPUS:0031724209

VL - 103

SP - 304

EP - 307

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -